Bristol-Myers Squibb Company (BMS) announced that Daklinza (daclatasvir), an NS5A replication complex inhibitor, has been approved on 24 July 2015...
BMS has announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has...
Bristol-Myers Squibb Company announced that the Japanese Ministry of Health, Labor and Welfare (MHLW) has approved Daklinza (daclatasvir), a potent,...
Bristol-Myers Squibb Company (BMS) has announced that the European Commission has approved Daklinza (daclatasvir) for the treatment of chronic hepatitis...
The National Institute for Health and Care Excellence (NICE) has recommended daclatasvir (Daklinza) from BMS in combination with sofosbuvir (Sovaldi) to...
Bristol-Myers Squibb has announced that the National Institute for Health and Care Excellence (NICE) has recommended Daklinza (daclatasvir) in England...
Bristol-Myers Squibb Company announced that the European Commission has approved Daklinza (daclatasvir), a potent, pan-genotypic NS5A replication complex inhibitor (in...
BMS announced that the European Commission has approved an updated label for Daklinza (daclatasvir) for the treatment of genotype 3...
BMS announced late-breaking data from the Phase III ALLY-3 trial investigating a regimen of Daklinza (daclatasvir, DCV) in combination with...
Bristol-Myers Squibb announced that the FDA has accepted for filing and review three supplemental New Drug Applications (sNDAs) for Daklinza...